The overall prognosis of patients with breast cancer brain metastases (BCBMs) remains very poor, with a median overall survival (OS) of 8.7 months and only 4.9 months for the triple-negative (ER–, PR–, HER2–) type [3]. The gene discussed is ERBB2; the disease is breast carcinoma.